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Identity 
Alias: Diaphyseal aclasis 
Inheritance: Autosomal dominant disorder, genetically 
heterogeneous; males are more often affected, possibly 
partly due to an incomplete penetrance in females; 
approximately 62% of the patients have a positive 
family history. 
Clinics 
Phenotype and clinics 
Presence of multiple osteochondromas 
(osteocartilaginous exostosis), bony protrusions 
covered by a cartilaginous cap on the outer surface of 
bone, resulting in a variety of orthopaedic deformities 
such as disproportionate short stature and bowing of the 
forearm; osteochondromas are the most common 
benign bone tumours,  
representing approximately 50% of all primary benign 
tumours of bone; they gradually develop and increase 
in size in the first decade of life; the stratified zones of 
chondrocytes that are normally found in the growth 
plate can still be recognised on the interface of cartilage 
and bone in osteochondroma; consequently, 
osteochondromas cease growing as the growth plates 
close during puberty; the majority is asymptomatic and 
is located in bones that developed from cartilage, 
especially the long bones in the extremities. 
Neoplastic risk 
Malignant transformation is low in solitary 
osteochondromas (<1%) but is estimated to occur in 1-
5% of cases of hereditary multiple exostoses. 
Treatment 
Osteochondromas can be surgically removed for 
cosmetic or functional reasons. 
 
 

















Cytogenetics of cancer 
Clonal karyotypic abnormalities in the cartilaginous 
cap of osteochondroma involving 8q22-24.1 were 
found in ten out of 30 sporadic and in 1 out of 13 
hereditary osteochondromas, supporting a neoplastic 
origin; this was confirmed since aneuploidy was found 
in 4 out of 10 osteochondromas and LOH was almost 
exclusively found at the EXT1 locus in 5 out of 14 
osteochondromas; no somatic EXT1 cDNA alterations 
were found in sporadic osteochondromas. 
Genes involved and proteins 
EXT1 and EXT2 
Location 
8q24 and 11p11-p12. 
Note 
HME is a genetically heterogeneous disorder for which 
at present, two genes, EXT1 and EXT2 located 
respectively on 8q24 and 11p11-p12, have been 
isolated; the EXT1 gene was reported to show linkage 
in 44%-66% of the HME families, whereas EXT2 
would be involved in 27%; additional linkage to 
chromosome 19p has been found, suggesting the 
existence of an EXT3 -gene, although loss of 
heterozygosity studies could not confirm this; two 
patients with multiple osteochondromas demonstrated a 
germline mutation in EXT1 combined with loss of the 
remaining wild type allele in three osteochondromas, 
confirming the tumour suppressor function of the EXT 
genes and indicating that in cartilaginous cells of the 
growth plate inactivation of both copies of the EXT1-
gene is required for osteochondroma formation in 
hereditary cases. 
Protein 
Function: A tumour suppressor function is suggested 
for the EXT genes, which was confirmed by the 
combination of EXT1 germline mutations with loss of 
the remaining wildtype allele in osteochondroma; the 
EXT gene products were shown to be involved in 
heparan sulphate biosynthesis. 
Mutations 
Germinal: Germline mutations of EXT1 and EXT2 in 
HME patients have been studied extensively in 
Caucasian as well as Asian populations. 
Somatic: No somatic mutations were found in the 
EXT1 and EXT2 gene in 34 sporadic and hereditary 
osteochondromas and chondrosarcomas tested. 
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